What We Do
Our Mission is to Revolutionize Pulmonary Care and Save Lives by Curing Lung Disease
BioSuperior Technology, Inc. is a preclinical stage biotherapeutics company developing cost-effective, non-invasive, and easily accessible technologies to cure lung disease and repair damaged lung tissue.
Discover BioSuperior
Gain insights into BioSuperior, its innovative bio-engineered lung surfactant, BioSurf, and the progress the team has made to date.
Bio-engineered Lung Surfactant – BioSurf
We have bio-engineered a novel synthetic pulmonary surfactant prototype, BioSurf, an essential biomaterial required for breathing. BioSurf has direct therapeutic effects and will be used to deliver potent drugs that restore normal lung function. We have overcome key technical issues that have limited the efficacy of other synthetic lung surfactants.
Beyond the pulmonary field, we expect that our technology platforms will be applicable to the treatment of other illnesses related to the microvasculature, including hemorrhagic stroke and chronic kidney disease.
More Information
Learn More About Lung Disease and Other Related Topics
The Team
We are a team of deeply experienced pharmaceutical scientists who have each helped discover and/or develop therapeutics that have reached $1B+ in annual sales.
RUSS LEHRMAN, PHD
Founder, President
Russ Lehrman is the Founder and President of BioSuperior Technology. He was also a Co-Founder and the VP of Chemistry at SnapDNA. In that position, he helped raise $5M. He is also an expert witness and serves as a Stanford University SPARK Advisor. Previously, Russ had technical leadership positions at Elan, InteKrin, Nektar, NeXstar, and Pfizer (Upjohn). He is an expert in pharmaceutical R&D with an emphasis on large molecule therapeutics. Russ received his Ph.D. in Medicinal Chemistry at UW-Madison.
LUCIA MOKRES, DVM
VP of Clinical and Regulatory Development
Lucia Mokres is the Founder and Principal of Araneae Biotech Consulting, LLC. She was previously the Chief Medical Officer of EpiBiome, Inc. Lucia has helped raise $6M in seed and Series A funding for that company. She is also on the Advisory Board of the Association for Women in Science. Previously, she was Principal Clinical Scientist at Abbott Vascular. Lucia was trained as a veterinarian at Colorado State University.
HONG ZHAO, MS
Senior Director of Chemistry, Manufacturing and Control
Hong Zhao has over 25 years of experience developing protein therapeutics. She has deep experience in CMC activities, including Clinical Supply, and Quality and Regulatory aspects of drug development at all stages of Clinical Development. She has managed internal and external operations and has prepared numerous CTD sections of regulatory filings. Hong received a M.S. in Chemistry from the Chinese Academy of Sciences.
EHUD GOLDIN, PHD
VP of Biology R&D
Ehud (Udi) Goldin is the Chief Scientific Officer of Angular Medicine. He is also a Stanford University SPARK Advisor. Earlier Ehud was Chief Scientist at SENS Research and senior staff fellow at the National Institutes of Health (NINDS and NHGRI). Ehud is expert in diseases resulting from lipid netabolic disorders. He received his Ph.D. in Neurochemistry from the Weizmann Institute in Israel.
RUSS LEHRMAN, PHD
Founder, President
Russ Lehrman is the Founder and President of BioSuperior Technology. He was also a Co-Founder and the VP of Chemistry at SnapDNA. In that position, he helped raise $5M. He is also an expert witness and serves as a Stanford University SPARK Advisor. Previously, Russ had technical leadership positions at Elan, InteKrin, Nektar, NeXstar, and Pfizer (Upjohn). He is an expert in pharmaceutical R&D with an emphasis on large molecule therapeutics. Russ received his Ph.D. in Medicinal Chemistry at UW-Madison.
LUCIA MOKRES, DVM
VP of Clinical and Regulatory Development
Lucia Mokres is the Founder and Principal of Araneae Biotech Consulting, LLC. She was previously the Chief Medical Officer of EpiBiome, Inc. Lucia has helped raise $6M in seed and Series A funding for that company. She is also on the Advisory Board of the Association for Women in Science. Previously, she was Principal Clinical Scientist at Abbott Vascular. Lucia was trained as a veterinarian at Colorado State University.
HONG ZHAO, MS
Senior Director of Chemistry, Manufacturing and Control
Hong Zhao has over 25 years of experience developing protein therapeutics. She has deep experience in CMC activities, including Clinical Supply, and Quality and Regulatory aspects of drug development at all stages of Clinical Development. She has managed internal and external operations and has prepared numerous CTD sections of regulatory filings. Hong received a M.S. in Chemistry from the Chinese Academy of Sciences.
EHUD GOLDIN, PHD
VP of Biology R&D
Ehud (Udi) Goldin is the Chief Scientific Officer of Angular Medicine. He is also a Stanford University SPARK Advisor. Earlier Ehud was Chief Scientist at SENS Research and senior staff fellow at the National Institutes of Health (NINDS and NHGRI). Ehud is expert in diseases resulting from lipid netabolic disorders. He received his Ph.D. in Neurochemistry from the Weizmann Institute in Israel.
Our Advisors
Jahar Bhattacharya, MD, DPhil
Professor of Medicine Division of Pulmonary and Critical Care Columbia University Medical College.
James Bridges, PH.D
Associate Professor National Jewish Heath Division of Pulmonary & Critical Care
Jeffrey Whitsett, MD
Section Chief, Division of Neonatology, Cincinnati Children’s Hospital Professor, University of Cincinnati Department of Pediatrics.
John Patton, PhD
Co-Founder of Inhale/Nektar (NKTR) in 1990 – ONSET. Founder, Director and Strategic Advisor Aerami Therapeutics/Dance Biopharm Holdings, Inc.
Elizabeth Redente, PhD
Associate Professor National Jewish Health Division of Cell Biology.